Alexandria — Pharco Pharmaceuticals has inaugurated a new ophthalmic drops production line at its Al Amreya facility, with investments of approximately $5.8 million (EGP 300 million), as part of a broader expansion programme valued at EGP 500 million.
The company stated that the new line will produce up to 20 million packs annually, covering nearly 19% of Egypt’s ophthalmic market, which exceeds 100 million packs per year. The production mix includes treatments for dry eye, glaucoma, inflammation, post-operative care, and allergies.
Officials from the Egyptian Drug Authority said the project supports efforts to localise pharmaceutical manufacturing, reduce reliance on imports, and expand exports to Middle East and African markets, in line with Egypt Vision 2030. The Unified Procurement Authority described the investment as a practical example of public-private cooperation in strengthening supply chains.
The expansion also includes a new penicillin production line and upgrades to sterile and semi-solid manufacturing units, supported by EU-GMP and WHO-compliant standards, alongside the introduction of digital quality systems and an integrated research and development centre.
The company reported annual sales exceeding 278 million units valued at nearly EGP 15 billion, underscoring its growing role in both domestic supply and export markets.
This development reflects a broader trend within Egypt’s pharmaceutical sector toward capacity expansion and specialisation, as manufacturers position themselves to meet rising regional demand and enhance export competitiveness.
